Marty Mullins
Physician Assistant · Hazard, KYNPI 1699778795
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,506 of the $63,478 with a category attached, or 87.4%. Esperion Therapeutics, Inc. accounts for 74.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $33,092 and has fallen 76.3% since, to $7,837 in 2025. Among physician assistant clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $261.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$47K
- Amgen$14K
- Kowa Pharmaceuticals America, Inc.$517
- Gilead$377
- AbbVie$358
- Johnson & Johnson$255
- plus $1K from 19 others
What the payments were for
- Consulting fees$5001%
- Speaking & faculty fees$55,50687%
- Travel & lodging$3,2085%
- Food & beverage$4,2637%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 85 | $47,330 |
| Amgen(2 entities) | 38 | $13,525 |
| Kowa Pharmaceuticals America, Inc. | 2 | $517 |
| Gilead | 17 | $377 |
| AbbVie | 19 | $358 |
| Johnson & Johnson | 19 | $255 |
| Dexcom, Inc. | 5 | $183 |
| Novo Nordisk | 9 | $151 |
| Biohaven Pharmaceuticals, Inc. | 8 | $122 |
| Daiichi Sankyo Inc. | 7 | $108 |
| Novartis | 4 | $103 |
| Lilly USA, LLC | 6 | $78 |
| GSK | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Pfizer | 2 | $33 |
| Pharmaessentia USA Corporation | 1 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Corium, LLC | 2 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Bayer | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$45,809
- NEXLETOL$45,809
- Repatha$13,254
- DEXCOM G7 GSS (161)$101
- DEXCOM STELO GLUCOSE BIOSENSOR$101
How this compares
$63,478 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $72,094 |
| MounjaroTirzepatide | 56 | $67,494 |
| OzempicSemaglutide | 44 | $42,077 |
| FarxigaDapagliflozin Propanediol | 42 | $41,307 |
| JardianceEmpagliflozin | 47 | $35,814 |
| TradjentaLinagliptin | 33 | $20,907 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $16,687 |
| JanuviaSitagliptin Phosphate | 12 | $14,805 |
| XareltoRivaroxaban | 12 | $14,348 |
| TrulicityDulaglutide | 14 | $12,613 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,656 |
| Repatha SureclickEvolocumab | 20 | $10,614 |
| NexlizetBempedoic Acid/Ezetimibe | 20 | $7,793 |
| JentaduetoLinagliptin/Metformin Hcl | 18 | $7,222 |
| LinzessLinaclotide | 13 | $6,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $78 | $80,10770 claims |
| PfizerEliquis | $33 | $72,09485 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $22 | $63,94398 claims |
| Novo NordiskOzempic | $151 | $42,07744 claims |
| Johnson & JohnsonXarelto | $255 | $14,34812 claims |
| Esperion Therapeutics, Inc.Nexlizet | $47,330 | $7,79320 claims |
| AbbVieLinzess, Synthroid | $358 | $7,19830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.
Other physician assistant in Hazard
- Crystal GibsonHazard$10K
- Brandice HarrisonLexington$745K
- Lauren MeadeLexington$656K
- Melissa DavisLouisville$362K
- Kara MuddLouisville$98K
- Seth KingBowling Green$91K
- Lauri GarnerVersailles$33K
- Robert TatumLouisville$29K
- Grace IsaacsLouisville$28K
- Catherine BookerProspect$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.